Paul Joseph Barreira, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Soccer | 5 | 2024 | 142 | 1.890 |
Why?
|
| Acceleration | 2 | 2024 | 189 | 1.010 |
Why?
|
| Employment, Supported | 6 | 2011 | 29 | 0.930 |
Why?
|
| Soft Tissue Injuries | 1 | 2024 | 172 | 0.830 |
Why?
|
| Rehabilitation, Vocational | 3 | 2011 | 81 | 0.590 |
Why?
|
| Athletic Injuries | 4 | 2024 | 1216 | 0.500 |
Why?
|
| Students | 3 | 2022 | 1741 | 0.490 |
Why?
|
| Community Mental Health Services | 5 | 2010 | 392 | 0.490 |
Why?
|
| Mental Disorders | 15 | 2012 | 6841 | 0.480 |
Why?
|
| Leg Injuries | 1 | 2016 | 179 | 0.460 |
Why?
|
| Rehabilitation | 1 | 2010 | 130 | 0.320 |
Why?
|
| Ticlopidine | 1 | 2014 | 730 | 0.320 |
Why?
|
| Desensitization, Immunologic | 1 | 2014 | 545 | 0.310 |
Why?
|
| Mental Health Services | 6 | 2008 | 1730 | 0.300 |
Why?
|
| Mental Health | 1 | 2022 | 3249 | 0.290 |
Why?
|
| Personal Autonomy | 1 | 2008 | 304 | 0.250 |
Why?
|
| Deceleration | 1 | 2024 | 10 | 0.240 |
Why?
|
| Drug Hypersensitivity | 1 | 2014 | 917 | 0.240 |
Why?
|
| Portugal | 1 | 2024 | 91 | 0.240 |
Why?
|
| Patient Participation | 3 | 2010 | 1444 | 0.230 |
Why?
|
| Muscle, Skeletal | 2 | 2016 | 4946 | 0.220 |
Why?
|
| Community Mental Health Centers | 2 | 2001 | 93 | 0.210 |
Why?
|
| Choice Behavior | 2 | 2008 | 824 | 0.210 |
Why?
|
| Universities | 2 | 2022 | 993 | 0.200 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2014 | 2751 | 0.190 |
Why?
|
| Social Support | 1 | 2011 | 2172 | 0.180 |
Why?
|
| Mumps virus | 1 | 2020 | 23 | 0.180 |
Why?
|
| Running | 1 | 2024 | 488 | 0.170 |
Why?
|
| Mumps | 1 | 2020 | 71 | 0.160 |
Why?
|
| Contract Services | 1 | 1999 | 89 | 0.160 |
Why?
|
| Schizophrenic Psychology | 2 | 2006 | 1647 | 0.150 |
Why?
|
| Evidence-Based Medicine | 1 | 2010 | 3687 | 0.150 |
Why?
|
| Certification | 3 | 2006 | 418 | 0.150 |
Why?
|
| Jogging | 1 | 2016 | 18 | 0.140 |
Why?
|
| Program Evaluation | 2 | 2010 | 2494 | 0.140 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2010 | 10203 | 0.130 |
Why?
|
| Genome, Viral | 1 | 2020 | 665 | 0.130 |
Why?
|
| Self-Injurious Behavior | 2 | 2012 | 566 | 0.120 |
Why?
|
| Muscle Strength | 1 | 2019 | 624 | 0.120 |
Why?
|
| Geographic Information Systems | 1 | 2016 | 281 | 0.120 |
Why?
|
| Propranolol | 3 | 1984 | 489 | 0.110 |
Why?
|
| Professional-Patient Relations | 2 | 2010 | 726 | 0.110 |
Why?
|
| Peer Group | 2 | 2011 | 692 | 0.110 |
Why?
|
| Motor Skills | 1 | 2016 | 520 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 2 | 2001 | 7389 | 0.110 |
Why?
|
| Immobilization | 1 | 2014 | 229 | 0.110 |
Why?
|
| Adult | 26 | 2024 | 221148 | 0.100 |
Why?
|
| Task Performance and Analysis | 1 | 2016 | 761 | 0.100 |
Why?
|
| Life Expectancy | 1 | 1999 | 1242 | 0.100 |
Why?
|
| Motivation | 2 | 2005 | 2006 | 0.100 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2000 | 942 | 0.100 |
Why?
|
| Anthropometry | 1 | 2016 | 1349 | 0.100 |
Why?
|
| Massachusetts | 6 | 2008 | 8832 | 0.090 |
Why?
|
| Muscular Atrophy | 1 | 2014 | 333 | 0.090 |
Why?
|
| Insurance, Psychiatric | 1 | 2010 | 69 | 0.090 |
Why?
|
| Disease Outbreaks | 1 | 2020 | 1749 | 0.090 |
Why?
|
| Male | 28 | 2024 | 360736 | 0.090 |
Why?
|
| Psychotic Disorders | 4 | 2004 | 3223 | 0.090 |
Why?
|
| Humans | 45 | 2024 | 761423 | 0.090 |
Why?
|
| Alcoholic Intoxication | 1 | 2011 | 174 | 0.080 |
Why?
|
| Health Services Research | 2 | 2009 | 1812 | 0.080 |
Why?
|
| Schizophrenia | 4 | 2006 | 6937 | 0.080 |
Why?
|
| Muscle Proteins | 1 | 2014 | 1154 | 0.080 |
Why?
|
| Akathisia, Drug-Induced | 3 | 1984 | 67 | 0.070 |
Why?
|
| Health Benefit Plans, Employee | 1 | 2010 | 333 | 0.070 |
Why?
|
| Ultrasonography, Interventional | 1 | 2016 | 1495 | 0.070 |
Why?
|
| Substance-Related Disorders | 2 | 2004 | 4420 | 0.070 |
Why?
|
| Psychomotor Agitation | 3 | 1984 | 305 | 0.070 |
Why?
|
| Psychiatry | 1 | 1999 | 1692 | 0.070 |
Why?
|
| Anxiety | 1 | 2022 | 4572 | 0.070 |
Why?
|
| Psychotropic Drugs | 1 | 1992 | 888 | 0.070 |
Why?
|
| Medicaid | 2 | 2004 | 2818 | 0.070 |
Why?
|
| Health Policy | 1 | 1999 | 2684 | 0.070 |
Why?
|
| Emotions | 1 | 2018 | 2739 | 0.070 |
Why?
|
| Models, Organizational | 2 | 2000 | 546 | 0.070 |
Why?
|
| Incidence | 1 | 2024 | 21341 | 0.070 |
Why?
|
| Quality Assurance, Health Care | 3 | 2001 | 2169 | 0.060 |
Why?
|
| Self-Help Groups | 1 | 2006 | 192 | 0.060 |
Why?
|
| Patient Acceptance of Health Care | 2 | 2010 | 3204 | 0.060 |
Why?
|
| Random Allocation | 1 | 2009 | 2394 | 0.060 |
Why?
|
| Obsessive-Compulsive Disorder | 1 | 1994 | 1491 | 0.060 |
Why?
|
| Vertigo | 1 | 2006 | 202 | 0.060 |
Why?
|
| Time Factors | 3 | 2024 | 39975 | 0.060 |
Why?
|
| Body Composition | 1 | 2014 | 2422 | 0.060 |
Why?
|
| Young Adult | 5 | 2024 | 59207 | 0.060 |
Why?
|
| Thirst | 1 | 1984 | 42 | 0.060 |
Why?
|
| Employment | 1 | 2010 | 1118 | 0.060 |
Why?
|
| Inappropriate ADH Syndrome | 1 | 1984 | 61 | 0.060 |
Why?
|
| Antidepressive Agents | 2 | 1988 | 2897 | 0.060 |
Why?
|
| Metoprolol | 1 | 1984 | 90 | 0.060 |
Why?
|
| Paranoid Disorders | 1 | 1983 | 61 | 0.060 |
Why?
|
| Drinking Behavior | 1 | 1984 | 103 | 0.050 |
Why?
|
| Hospitals, Psychiatric | 2 | 2001 | 321 | 0.050 |
Why?
|
| Research Subjects | 1 | 2005 | 249 | 0.050 |
Why?
|
| Suicidal Ideation | 1 | 2012 | 1444 | 0.050 |
Why?
|
| Diffusion of Innovation | 1 | 2007 | 728 | 0.050 |
Why?
|
| Paroxetine | 1 | 2003 | 182 | 0.050 |
Why?
|
| Program Development | 1 | 2008 | 1298 | 0.050 |
Why?
|
| New York City | 2 | 2007 | 731 | 0.050 |
Why?
|
| Needs Assessment | 1 | 2008 | 1139 | 0.050 |
Why?
|
| Suicide | 1 | 2012 | 1598 | 0.050 |
Why?
|
| Exercise | 1 | 2018 | 5884 | 0.050 |
Why?
|
| Assertiveness | 1 | 2001 | 18 | 0.050 |
Why?
|
| Commitment of Mentally Ill | 1 | 2001 | 94 | 0.050 |
Why?
|
| Data Collection | 1 | 2010 | 3322 | 0.050 |
Why?
|
| Health Surveys | 1 | 2011 | 4059 | 0.050 |
Why?
|
| Group Homes | 1 | 2001 | 59 | 0.040 |
Why?
|
| Antipsychotic Agents | 4 | 1992 | 3068 | 0.040 |
Why?
|
| Benchmarking | 2 | 2010 | 1045 | 0.040 |
Why?
|
| Bereavement | 1 | 2004 | 308 | 0.040 |
Why?
|
| Muscle Strength Dynamometer | 1 | 2019 | 41 | 0.040 |
Why?
|
| Dementia | 1 | 1994 | 2686 | 0.040 |
Why?
|
| Fluoxetine | 1 | 2003 | 733 | 0.040 |
Why?
|
| Female | 23 | 2018 | 392581 | 0.040 |
Why?
|
| Memory Disorders | 1 | 2006 | 1198 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2016 | 20093 | 0.040 |
Why?
|
| Proprioception | 1 | 2019 | 133 | 0.040 |
Why?
|
| Models, Neurological | 1 | 2006 | 1767 | 0.040 |
Why?
|
| Molecular Epidemiology | 1 | 2020 | 469 | 0.040 |
Why?
|
| Bipolar Disorder | 5 | 1999 | 5091 | 0.040 |
Why?
|
| Cooperative Behavior | 2 | 2007 | 1504 | 0.040 |
Why?
|
| Sampling Studies | 1 | 2018 | 615 | 0.030 |
Why?
|
| Public Health Administration | 1 | 1999 | 242 | 0.030 |
Why?
|
| Placebos | 1 | 2001 | 1667 | 0.030 |
Why?
|
| Depressive Disorder | 2 | 1988 | 3728 | 0.030 |
Why?
|
| United States | 9 | 2020 | 72339 | 0.030 |
Why?
|
| Ethics, Medical | 1 | 2001 | 783 | 0.030 |
Why?
|
| Quality Improvement | 1 | 2011 | 3800 | 0.030 |
Why?
|
| Behavior Therapy | 1 | 2001 | 880 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2011 | 15262 | 0.030 |
Why?
|
| Body Fluid Compartments | 1 | 2014 | 50 | 0.030 |
Why?
|
| Life Change Events | 2 | 2012 | 952 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2016 | 36423 | 0.030 |
Why?
|
| Depressive Disorder, Major | 2 | 2003 | 4760 | 0.030 |
Why?
|
| Middle Aged | 12 | 2011 | 220826 | 0.030 |
Why?
|
| Teaching | 1 | 2001 | 1169 | 0.030 |
Why?
|
| Patient Care Team | 2 | 2001 | 2523 | 0.030 |
Why?
|
| Viral Proteins | 1 | 2020 | 1803 | 0.030 |
Why?
|
| Metabolic Clearance Rate | 1 | 1992 | 361 | 0.030 |
Why?
|
| Phylogeny | 1 | 2020 | 2811 | 0.030 |
Why?
|
| Aged | 6 | 2014 | 169235 | 0.020 |
Why?
|
| Habituation, Psychophysiologic | 1 | 2012 | 147 | 0.020 |
Why?
|
| Prefrontal Cortex | 1 | 2003 | 2218 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2005 | 3600 | 0.020 |
Why?
|
| Hypertrophy | 1 | 2014 | 559 | 0.020 |
Why?
|
| Solutions | 1 | 1992 | 412 | 0.020 |
Why?
|
| Biological Availability | 1 | 1992 | 390 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 1999 | 2426 | 0.020 |
Why?
|
| Resistance Training | 1 | 2014 | 193 | 0.020 |
Why?
|
| Length of Stay | 2 | 2001 | 6422 | 0.020 |
Why?
|
| Knee Joint | 1 | 2019 | 1673 | 0.020 |
Why?
|
| Social Adjustment | 1 | 2012 | 632 | 0.020 |
Why?
|
| Homosexuality | 1 | 2011 | 267 | 0.020 |
Why?
|
| Cerebral Cortex | 1 | 2006 | 5776 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2004 | 9320 | 0.020 |
Why?
|
| Severity of Illness Index | 3 | 2006 | 15838 | 0.020 |
Why?
|
| Adolescent | 7 | 2019 | 88313 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2011 | 39117 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 1994 | 1834 | 0.020 |
Why?
|
| Insurance, Health | 1 | 2001 | 2497 | 0.020 |
Why?
|
| Dietary Carbohydrates | 1 | 2014 | 891 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2020 | 4741 | 0.020 |
Why?
|
| Cause of Death | 1 | 1999 | 3684 | 0.020 |
Why?
|
| Atrophy | 1 | 1994 | 1633 | 0.020 |
Why?
|
| Dietary Proteins | 1 | 2014 | 952 | 0.020 |
Why?
|
| Anger | 1 | 2011 | 406 | 0.020 |
Why?
|
| Parent-Child Relations | 1 | 2012 | 761 | 0.020 |
Why?
|
| Vaccination | 1 | 2020 | 3381 | 0.020 |
Why?
|
| Parkinson Disease, Secondary | 2 | 1984 | 122 | 0.020 |
Why?
|
| Patient Dropouts | 1 | 2009 | 412 | 0.020 |
Why?
|
| Organizational Case Studies | 1 | 2007 | 301 | 0.020 |
Why?
|
| Lithiasis | 1 | 2006 | 19 | 0.020 |
Why?
|
| Cross-Sectional Studies | 3 | 2019 | 26112 | 0.020 |
Why?
|
| Retrospective Studies | 3 | 2011 | 80582 | 0.020 |
Why?
|
| Haloperidol | 2 | 1984 | 389 | 0.020 |
Why?
|
| Pilot Projects | 1 | 1999 | 8633 | 0.020 |
Why?
|
| Researcher-Subject Relations | 1 | 2005 | 15 | 0.020 |
Why?
|
| Genotype | 1 | 2020 | 13009 | 0.020 |
Why?
|
| Amantadine | 1 | 1984 | 57 | 0.010 |
Why?
|
| Thioridazine | 1 | 1984 | 33 | 0.010 |
Why?
|
| Perphenazine | 1 | 1984 | 33 | 0.010 |
Why?
|
| Administration, Oral | 1 | 1992 | 4016 | 0.010 |
Why?
|
| Doxepin | 1 | 1983 | 16 | 0.010 |
Why?
|
| Phenelzine | 1 | 1983 | 28 | 0.010 |
Why?
|
| Imipramine | 1 | 1983 | 98 | 0.010 |
Why?
|
| Vestibular Diseases | 1 | 2006 | 230 | 0.010 |
Why?
|
| Amitriptyline | 1 | 1983 | 112 | 0.010 |
Why?
|
| Body Weight | 1 | 2014 | 4618 | 0.010 |
Why?
|
| Dyskinesia, Drug-Induced | 1 | 1983 | 165 | 0.010 |
Why?
|
| Water-Electrolyte Balance | 1 | 1984 | 325 | 0.010 |
Why?
|
| Health Services Needs and Demand | 1 | 2011 | 1403 | 0.010 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2005 | 257 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 1992 | 2319 | 0.010 |
Why?
|
| Mothers | 1 | 2012 | 2192 | 0.010 |
Why?
|
| Hospitals, State | 1 | 2001 | 28 | 0.010 |
Why?
|
| Adipose Tissue | 1 | 2014 | 3312 | 0.010 |
Why?
|
| Licensure, Hospital | 1 | 2001 | 2 | 0.010 |
Why?
|
| Hospitalization | 1 | 2001 | 10718 | 0.010 |
Why?
|
| Caudate Nucleus | 1 | 2003 | 389 | 0.010 |
Why?
|
| Hyponatremia | 1 | 1984 | 279 | 0.010 |
Why?
|
| Hospitals, Private | 1 | 2001 | 63 | 0.010 |
Why?
|
| Delusions | 1 | 1983 | 298 | 0.010 |
Why?
|
| Attitude to Death | 1 | 2004 | 400 | 0.010 |
Why?
|
| Parietal Lobe | 1 | 2006 | 851 | 0.010 |
Why?
|
| Risk | 1 | 2012 | 9612 | 0.010 |
Why?
|
| Restless Legs Syndrome | 1 | 1983 | 233 | 0.010 |
Why?
|
| Insurance Claim Review | 1 | 2004 | 741 | 0.010 |
Why?
|
| Hospitals, Public | 1 | 2001 | 202 | 0.010 |
Why?
|
| Interviews as Topic | 1 | 2007 | 2696 | 0.010 |
Why?
|
| Respiratory Sounds | 1 | 1984 | 701 | 0.010 |
Why?
|
| Functional Laterality | 1 | 2006 | 2256 | 0.010 |
Why?
|
| Risk Factors | 2 | 2012 | 74167 | 0.010 |
Why?
|
| Costs and Cost Analysis | 1 | 2004 | 1668 | 0.010 |
Why?
|
| Temporal Lobe | 1 | 2006 | 1695 | 0.010 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 1984 | 1241 | 0.010 |
Why?
|
| Psychomotor Performance | 1 | 2006 | 1879 | 0.010 |
Why?
|
| Sex Factors | 1 | 2011 | 10548 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2012 | 14599 | 0.010 |
Why?
|
| Dexamethasone | 1 | 1983 | 1947 | 0.010 |
Why?
|
| Logistic Models | 1 | 2011 | 13255 | 0.010 |
Why?
|
| Demography | 1 | 2001 | 1648 | 0.010 |
Why?
|
| Mutation | 1 | 2020 | 30045 | 0.010 |
Why?
|
| Neurons | 1 | 1994 | 9462 | 0.010 |
Why?
|
| Oxygen | 1 | 2006 | 4228 | 0.010 |
Why?
|
| History, 20th Century | 1 | 2001 | 2769 | 0.010 |
Why?
|
| Hippocampus | 1 | 2006 | 3763 | 0.010 |
Why?
|
| Acute Disease | 1 | 1984 | 7238 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 2006 | 7045 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2005 | 3460 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2005 | 10089 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 1988 | 8000 | 0.010 |
Why?
|
| Anxiety Disorders | 1 | 1983 | 2717 | 0.010 |
Why?
|
| Cognition Disorders | 1 | 2006 | 3979 | 0.010 |
Why?
|
| Health Status | 1 | 2004 | 4075 | 0.010 |
Why?
|
| Brain Mapping | 1 | 2006 | 6626 | 0.010 |
Why?
|
| Proportional Hazards Models | 1 | 2005 | 12456 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 1994 | 20556 | 0.010 |
Why?
|
| Comorbidity | 1 | 2004 | 10498 | 0.010 |
Why?
|
| Insurance Coverage | 1 | 2001 | 1940 | 0.010 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2004 | 3204 | 0.010 |
Why?
|
| Research Design | 1 | 2005 | 6178 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2001 | 8529 | 0.000 |
Why?
|
| Double-Blind Method | 1 | 2003 | 12330 | 0.000 |
Why?
|
| Blood Pressure | 1 | 1984 | 8487 | 0.000 |
Why?
|
| Case-Control Studies | 1 | 2006 | 22168 | 0.000 |
Why?
|
| Diagnosis, Differential | 1 | 1983 | 12970 | 0.000 |
Why?
|
| Brain | 1 | 1994 | 27107 | 0.000 |
Why?
|
| Medicare | 1 | 2001 | 6770 | 0.000 |
Why?
|
| Drug Tolerance | 1 | 1984 | 367 | 0.000 |
Why?
|
| Lithium | 1 | 1984 | 596 | 0.000 |
Why?
|
| Hydrocortisone | 1 | 1983 | 1815 | 0.000 |
Why?
|